Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018
MARKET OUTLOOK
Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated patients, but newer therapies including two IL-17 inhibitors have a growing market share. Persistency and compliance are highest for Remicade, but Enbrel and Humira continue to capture the largest portion of the bDMARD market.
QUESTIONS ANSWERED
- How long do patients wait between a diagnosis and an initial prescription? How fast do newly diagnosed patients progress through lines of therapy?
- Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?
- What changes have taken place in the treatment algorithm within the last three years? What therapies have a growing or shrinking market share?
- How compliant are PsA patients with their prescribed medication? What medications have the highest persistency?
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
